Opendata, web and dolomites

3DCC

Ready-to-use 3D Cell Cultures for early de-risking in drug development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DCC project word cloud

Explore the words cloud of the 3DCC project. It provides you a very rough idea of what is the project "3DCC" about.

cagr    clinical    reagents    candidate    manually    companies    progress    466    assays    compounds    largely    market    opportunity    tailor    23    spheroid    pipeline    unacceptable    big    37    efficacy    tissue    strategy    solution    disposable    models    broad    drugs    format    fail    effect    trials    global    thanks    capitalizing    biopharmaceutical    supply    million    345    expensive    appears    ready    niches    eliminate    pharmaceutical    stem    96    10    commodity    buy    toxicity    programs    plate    advantages    treatment    pharma    sera    standard    industry    successfully    compatibility    latest    stemtek    kits    establishes    csc    enter    cultures    report    precisely    bcc    profile    drug    cell    cancer    integration    made    company    800    3dcc    2016    media    business    2021    seven       economies    usd    biological    enriched    populations    3d    culture    lack    clear    facilities    markets    thriving    customers    competitive    120   

Project "3DCC" data sheet

The following table provides information about the project.

Coordinator
STEMTEK THERAPEUTICS SL 

Organization address
address: KABI 612 LABORATORIO 17 ASTONDO BIDEA S/N PARQUE TECHNOLOGICO Y CIENTIFICO DE BIZKAIA
city: DERIO
postcode: 48160
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.stemtektherapeutics.com/en/cell2sphere-kit
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STEMTEK THERAPEUTICS SL ES (DERIO) coordinator 50˙000.00

Map

 Project objective

StemTek is a global biopharmaceutical company with a clear stem cell focus in drug development for cancer treatment. Only about 10% of the candidate compounds progress successfully through clinical development. Many drugs fail during clinical trials, especially during phase III, which is the most expensive phase of clinical development, largely due to the lack of clinical efficacy and/or unacceptable toxicity.

StemTek is developing a solution to make cell based assays a commodity: easy to get, easy to buy, easy to use, and disposable, so we eliminate the need for large tissue culture facilities. This new solution is a ready-to-use 3D spheroid culture in standard 96 well plate format that allows customers to profile their pipeline of compounds for their effect on CSC populations using 3D culture models.

Thanks to the 3DCC, a business opportunity appears to develop a multi-million euro business capitalizing on the thriving interest from Pharma in finding novel biological testing systems based on 3D cell culture. Latest Markets&market report (2016) establishes that the global 3D cell culture market is expected to reach USD 1,345.2 M by 2021 from USD 466.8 M in 2016 at a CAGR of 23.6% (market growth). According to BCC research, from the seven different niches, “Reagents, media and sera” is precisely the most relevant (37.2 %). 3DCC objectives are: • To produce tailor made kits to improve compatibility with different drug development programs, leading to a broad range of applications. • To use all the competitive advantages of CSC enriched 3D spheroid cultures in ready to use standard 96 well plate format. • The large-scale production of ready to use kits to be able to enter/supply the pharmaceutical industry to achieve economies of scale, and go from current 800 kits/year (manually) up to 120.000 kits per year. • The integration of CSC testing into the drug development strategy of top 10 Big Pharma companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DCC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DCC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

HEADSpAcE (2019)

Translational studies of HEAD and neck cancer in South America and Europe

Read More  

BETTER-B (2019)

BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE

Read More